Search Results for: "Other News to Note"
-
Other News To Note
NGM Biopharmaceuticals Inc., of South San Francisco, and Medimmune, the global biologics research and development arm of Astrazeneca plc, of London, entered into an exclusive agreement to discover, develop and commercialize novel therapeutics from NGM's enteroendocrine cell (EEC) program for the treatment of Type II diabetes and obesityBioWorld Today | Tuesday, June 18, 2013 -
Other News To Note
According to Royalty, a "sufficient number of these ADSs" voted against Elan's proposed $1 billion cash acquisition of a royalty stream from South San Francisco-based Theravance IncBioWorld Today | Monday, June 17, 2013 -
Other News To Note
PDL Biopharma Inc., of Incline Village, Nev., filed a notice of arbitration against Genentech Inc. (part of Roche AG), of South San Francisco, with the American Arbitration Association in Voorhees, N.J., alleging, inter alia, that Genentech underpaid royalties going back to at least 2007 and impeded PDL's attempts to have Genentech's books and records inspected to determine whether Genentech's past payments to PDL were accurately calculatedBioWorld Today | Wednesday, June 12, 2013 -
Other News To Note
Hyperion Therapeutics Inc., of South San Francisco, said it completed the acquisition of Buphenyl (sodium phenylbutyrate) tablets and powder, from Ucyclyd Pharma Inc., a subsidiary of Valeant Pharmaceuticals International Inc., of Laval, Quebec, Buphenyl is indicated as adjunctive therapy in the chronic management of patients with urea cycle disorders (UCD...Onyx Pharmaceuticals Inc., of South San Francisco, and the University of California, San Francisco (UCSF) Helen Diller Family ComprehensiveBioWorld Today | Tuesday, June 4, 2013 -
Other News To Note
The Royalty offer was contingent on Elan's shareholders voting down all of its M&A transactions, including its recent $1 billion cash deal to buy a 21 percent stake in South San Francisco-based Theravance Inc.'s future royalty stream from the respiratory franchise it shares with London-based GlaxoSmithKline plcBioWorld International | Wednesday, May 29, 2013 -
Other News To Note
The Royalty offer was contingent on Elan's shareholders voting down all of its M&A transactions, including its recent $1 billion cash deal to buy a 21 percent stake in South San Francisco-based Theravance Inc.'s future royalty stream from the respiratory franchise it shares with London-based GlaxoSmithKline plcBioWorld Today | Friday, May 24, 2013 -
Other News To Note
Genmab A/S, of Copenhagen, Denmark, reported that South San Francisco-based Genentech Inc., a unit of the Roche Group, and Weston, Mass.-based Biogen Idec IncBioWorld International | Wednesday, May 22, 2013 -
Other News To Note
Genmab A/S, of Copenhagen, Denmark, reported that South San Francisco-based Genentech Inc., a unit of the Roche Group, and Weston, Mass.-based Biogen Idec IncBioWorld Today | Monday, May 20, 2013 -
Other News To Note
Curis earned a $4 million milestone payment from Genentech Inc., of South San Francisco (a unit of Roche AG), as a result of the Australian approvalBioWorld Today | Monday, May 13, 2013 -
Other News To Note
VistaGen Therapeutics Inc., of South San Francisco, said its human pluripotent stem cell-derived cardiomyocytes were used by collaboration partner Duke University to grow three-dimensional (3D) human heart muscleBioWorld Today | Wednesday, May 8, 2013 -
Other News To Note
Hyperion Therapeutics Inc., of South San Francisco, said the FDA notified the firm that Ravicti (glycerol phenylbutyrate) qualified for orphan drug exclusivity, giving the product exclusivity on the market for seven years from the date of approval on Feb. 1BioWorld Today | Friday, May 3, 2013 -
Other News To Note
Genentech Inc., of South San Francisco, a member of the Roche Group, said the FDA approved Actemra (tocilizumab) for the treatment of polyarticular juvenile idiopathic arthritis (PJIABioWorld Today | Wednesday, May 1, 2013 -
Other News To Note
Theravance Inc., of South San Francisco, said its board approved plans to separate its businesses into two independently traded companiesBioWorld Today | Monday, April 29, 2013 -
Other News To Note
Achaogen Inc., of South San Francisco, was awarded a $60 million contract option from the Biomedical Advanced Research and Development Authority (BARDA) supporting a global Phase III superiority study that will evaluate the efficacy and safety of plazomicin in treating patients with serious Gram-negative bacterial infections due to Carbapenem-resistant EnterobacteriaceaeBioWorld Today | Thursday, April 25, 2013 -
Other News To Note
Addex Therapeutics SA, of Geneva, reported preclinical data showing that its mGlu5 negative allosteric modulator oral small molecule, dipraglurant, dose-dependently prevented the abnormal excitatory effect observed on brain slices of transgenic primary generalized torsion dystonia 1 (DYT1) mice overexpressing the human mutant TOR1A gene by decreasing the paradoxical neuronal activity induced by the dopamine D2 receptor agonist quinpirole. DYT1 is a common and severe genetic form of dystoniaBioWorld International | Wednesday, April 24, 2013 -
Other News To Note
KaloBios Pharmaceuticals, of South San Francisco, and partner Sanofi Pasteur, of Lyon, France, said the FDA granted fast-track designation for the monoclonal antibody KB001A for protecting against bacterial pneumonia caused by Pseudomonas aeruginosa in mechanically-ventilated patientsBioWorld Today | Wednesday, April 24, 2013 -
Other News To Note
Evotec AG, of Hamburg, Germany, said it extended its drug discovery alliance with Genentech Inc., of South San Francisco, a member of the Roche Group, for three additional years...Theravance Inc., of South San Francisco, and GlaxoSmithKline plc, of London, submitted a regulatory application in Japan for once-daily LAMA/LABA combination medicine, UMEC/VI, for chronic obstructive pulmonary disease patientsBioWorld Today | Tuesday, April 23, 2013 -
Other News To Note
Genmab A/S, of Copenhagen, Denmark, said the Court of Appeals for the Federal Circuit upheld the District Court's judgment in favor of partner GlaxoSmithKline plc, of London, in a patent infringement case involving Arzerra (ofatumumab) brought against GSK by South San Francisco-based Genentech Inc. (now part of Roche AG) and Weston, Mass.-based Biogen Idec IncBioWorld Today | Wednesday, April 17, 2013 -
Other News To Note
The Genome Institute of Singapore and Fluidigm Corp., of South San Francisco, opened a new research center in Singapore, the Single-Cell Omics CentreBioWorld Today | Monday, April 15, 2013 -
Other News To Note
Cytokinetics Inc., of South San Francisco, received an award from Families of Spinal Muscular Atrophy to support preclinical research on muscle function in a mouse model of spinal muscular atrophy conducted with the firm's fast skeletal muscle troponin activator, tirasemtivBioWorld Today | Friday, April 5, 2013
Category
BioWorld | 3525 Piedmont Road
Building 6, Suite 400 | Atlanta, Georgia 30305, USA
Building 6, Suite 400 | Atlanta, Georgia 30305, USA
Part of Thompson Media Group LLC
Free Ezine
Sign up for Perspectives FREE e-mail newsletter.
Customer Service: In the U.S. and Canada: 1-800-477-6307
Outside the U.S.: 1-404-262-5423
customerservice@bioworld.com
Hours: Monday - Thursday, 8:30 am - 6:00 pm EST
Friday, 8:30am - 4:30 pm EST
Outside the U.S.: 1-404-262-5423
customerservice@bioworld.com
Hours: Monday - Thursday, 8:30 am - 6:00 pm EST
Friday, 8:30am - 4:30 pm EST
Copyright @ 2013 AHC Media. Reproduction, reposting content is strictly prohibited.